A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102

INtravesical Phase 1/1b Study of STING Agonist E7766 in NMIBC Including Subjects Unresponsive to BCG Therapy, INPUT-102

This is an open label, multicenter, phase 1/1b study to assess safety/tolerability and preliminary clinical activity of E7766 as a single agent administered intravesically in participants with NMIBC. Both intermediate risk and BCG-unresponsive NMIBC participants will be included.

Study Overview

• Status: Withdrawn
• Conditions: Urinary Bladder Neoplasms
• Intervention / Treatment: Drug: E7766

Detailed Description

The Phase 1/1b study consist of two parts: Dose Escalation and Dose Expansion. In the Dose Escalation Part, E7766 will be administered intravesically to participants with intermediate risk NMIBC or participants with BCG unresponsive NMIBC with increased dose levels to assess safety/tolerability profile of E7766 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of E7766. In the Dose Expansion Part, E7766 at RP2D will be administered to participants with NMIBC with or without carcinoma in situ (CIS) to confirm safety and assess preliminary clinical activity of E7766 as a single agent. Clinical activity will be evaluated by complete response (CR) rates at 3 months, 6 months, 12 months, 18 months, 24 months, and by duration of complete response (DOCR) in all participants who have achieved CR on treatment with E7766.

• Study Type: Interventional
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Arizona
    • Gilbert, Arizona, United States, 85234
      • Banner MD Anderson Cancer Center
  • California
    • Los Angeles, California, United States, 90033
      • University of Southern California
    • Santa Monica, California, United States, 90404
      • UCLA
  • Florida
    • Jacksonville, Florida, United States, 32224
      • Mayo Clinic Jacksonville
  • Indiana
    • Indianapolis, Indiana, United States, 46202
      • Indiana University
  • Missouri
    • Saint Louis, Missouri, United States, 63110
      • Washington University
  • New York
    • New York, New York, United States, 10029
      • The Mount Sinai Hospital
  • Ohio
    • Cleveland, Ohio, United States, 44195
      • Cleveland Clinic
    • Columbus, Ohio, United States, 43210
      • Ohio State University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
2. Life expectancy greater than (>) 2 years in the view of the investigator.
3. Participants must have biopsy proven transitional or predominantly transitional cell NMIBC.

4. For the Dose Escalation part of the study, the following participants will be included:

   1. Both, lower and higher dose escalation cohorts:

      Participants with intermediate risk NMIBC

   2. Only higher dose escalation cohorts:

   Participants with BCG Unresponsive NMIBC despite prior adequate treatment. Furthermore, all participants should be indicated for radical cystectomy as the standard of care for BCG unresponsive NMIBC. Participants who are undergoing radical cystectomy as well as participants who have refused to undergo radical cystectomy will be eligible to participate in the Dose Escalation part of the study. For participants who are undergoing radical cystectomy, date of surgery should not be delayed more than 3 months after Day 1 of dosing.

   For the Dose Expansion part of the study, the following participants will be included:

   Participants with histologically confirmed

   1. CIS (with or without concomitant non-muscle invasive, Ta or T1 papillary disease) (Arm 1) Or
   2. Non-muscle invasive high-grade Ta or T1 papillary disease without CIS (Arm 2) that is deemed to be unresponsive to BCG therapy despite prior adequate treatment. Furthermore, participants should be indicated for radical cystectomy as the standard of care for BCG unresponsive NMIBC but have refused to undergo radical cystectomy.

   Intermediate risk NMIBC: is defined as any participant with a high-grade Ta less than or equal to (<=) 3 cm or low-grade T1 tumor or with histologically confirmed multiple and/or recurrent low-grade Ta tumor with either 1 or 2 of the following 4 factors

   1. Multiple tumors
   2. Tumor >3 centimeter (cm)
   3. Early recurrence (less than [<] year)
   4. Frequent recurrences (>1 per year)

   BCG Unresponsive NMIBC is defined as being at least 1 of the following:

   1. Persistent or recurrent CIS alone or with recurrent Ta/T1 (noninvasive papillary disease/tumor invades the subepithelial connective tissue) disease within 12 months of completion of adequate BCG therapy.
   2. Recurrent high-grade Ta/T1 disease within 6 months of completion of adequate BCG therapy.
   3. T1 high-grade disease at the first evaluation following an induction BCG course

   Adequate BCG therapy is defined as at least 1 of the following:

   1. At least 5 of 6 doses of an initial induction course plus at least 2 of 3 doses of maintenance therapy.
   2. At least 5 of 6 doses of an initial induction course plus at least 2 of 6 doses of a second induction course.
5. Participants must consent to repeat biopsies to allow the acquisition of fresh formalin-fixed paraffin embedded (FFPE) material (obtained within 8 weeks prior to treatment initiation with E7766)
6. Participants must consent to repeat blood draws as indicated in the schedule of assessments.
7. Participant must consent to providing cystectomy tumor sample in the event that cystectomy is performed following treatment with E7766.
8. Immunosuppressive doses of systemic medications, such as steroids or absorbed topical steroids (doses >10 milligram per day (mg/d) prednisone or equivalent) must be safely discontinued at least 4 weeks before study drug administration.
9. Participants with prior Hepatitis B or C are eligible if they have adequate liver function.
10. Left ventricular ejection fraction (LVEF) >50 percent (%) on echocardiography or multiple gate acquisition (MUGA) scan.
11. Adequate renal function, bone marrow function and liver function.

Exclusion Criteria:

1. Other malignancy active within the previous 2 years except for basal or squamous cell skin cancer, or CIS of the cervix or breast that has completed curative therapy.
2. Participants with any active autoimmune disease or a documented history of autoimmune disease, except for participants with vitiligo or resolved childhood asthma/atopy
3. Presence of concomitant upper tract urothelial carcinoma or urothelial carcinoma within the prostatic urethra or any other regional/metastatic disease.
4. Known human immunodeficiency virus (HIV) infection.
5. Active infection requiring therapy
6. Major surgery within 4 weeks before the first dose of study drug.
7. Concurrent medical condition requiring the use of immunosuppressive medications or immunosuppressive doses of systemic medications, such as steroids or absorbed topical steroids (doses >10 mg/d prednisone or equivalent).
8. Prolongation of corrected QT (corrected for QTc interval using Frederica's correction factors [QTcF]) interval to >480 millisecond (msec) when electrolytes balance is normal.
9. Significant cardiovascular impairment.
10. Use of illegal recreational drugs.
11. Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin [ß-hCG] (or human chorionic gonadotropin [hCG]) test with a minimum sensitivity of 25 International Units Per Liter (IU/L) or equivalent units of ß-hCG [or hCG]). A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug.
12. Currently enrolled in another clinical study or used any investigational drug or device within 28 days preceding Cycle 1 Day 1 (first dosing day).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Dose Escalation: NMIBC And BCG Unresponsive NMIBC	Drug: E7766; E7766, solution, intravesically.
Experimental: Dose Expansion: CIS With/Without Ta or T1	Drug: E7766; E7766, solution, intravesically.
Experimental: Dose Expansion: High-grade Ta or T1, Without CIS	Drug: E7766; E7766, solution, intravesically.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Dose Escalation Part: Number of Participants with Dose-limiting Toxicities (DLTs)	DLTs are any of the toxicities occurring during the 6 weeks of the Induction Cycle and assessed by the investigator as related to study drug. Toxicity will be evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v.5.0).	Baseline up to 6 weeks of the Induction Cycle (Cycle length is equal to [=] 6 weeks)
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)		Baseline up to 30 days after the last dose of study drug (approximately 42 months)
Dose Expansion Part: Complete Response Rate (CRR) at 3 Months		Up to 3 months
Dose Expansion Part: CRR at 6 Months		Up to 6 months
Dose Expansion Part: CRR at 12 Months		Up to 12 months
Dose Expansion Part: CRR at 18 Months		Up to 18 months
Dose Expansion Part: CRR at 24 Months		Up to 24 months

Secondary Outcome Measures

Outcome Measure	Time Frame
Dose Escalation Part: CRR at 3, 6, 12, 18 and 24 Months	At Months 3, 6, 12, 18, and 24
DOCR	From the date of first documented CR until the first documentation of confirmed disease recurrence (approximately 42 months)
Local Recurrence Free Rates	At Months 6, 12, 18, and 24
Cmax: Maximum Observed Plasma Concentration for E7766	Dose Escalation: Induction Phase: Day 1: 0-24 hour post dose; Day 15: 0-8 hour post dose; Maintenance Phase: Cycle 1: Day :0- 8 hours post dose; Dose Expansion: Induction Phase: Day 1, Day 15: 0-8 hour post dose (Cycle length is 3 weeks)
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for E7766	Dose Escalation: Induction Phase: Day 1: 0-24 hour post dose; Day 15: 0-8 hour post dose; Maintenance Phase: Cycle 1: Day :0- 8 hours post dose; Dose Expansion: Induction Phase: Day 1, Day 15: 0-8 hour post dose (Cycle length is 3 weeks)
AUC: Area Under the Plasma Concentration Versus Time Curve for E7766	Dose Escalation: Induction Phase: Day 1: 0-24 hour post dose; Day 15: 0-8 hour post dose; Maintenance Phase: Cycle 1: Day :0- 8 hours post dose; Dose Expansion: Induction Phase: Day 1, Day 15: 0-8 hour post dose (Cycle length is 3 weeks)

Collaborators and Investigators

• Sponsor: Eisai Inc.
• Collaborators: H3 Biomedicine Inc.

Study record dates

Study Major Dates

• Study Start (Actual): February 13, 2020
• Primary Completion (Anticipated): September 29, 2022
• Study Completion (Anticipated): September 29, 2022

Study Registration Dates

• First Submitted: August 27, 2019
• First Submitted That Met QC Criteria: September 27, 2019
• First Posted (Actual): September 30, 2019

Study Record Updates

• Last Update Posted (Actual): December 14, 2020
• Last Update Submitted That Met QC Criteria: December 10, 2020
• Last Verified: July 1, 2020

More Information

Terms related to this study

• Keywords: Carcinoma in situ; Non-Muscle Invasive Bladder Cancer; E7766; Intravesical administration; Ta or T1 Papillary Disease; Stimulator of Interferon Genes Agonist; BCG Unresponsive
• Additional Relevant MeSH Terms: Neoplasms; Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Urologic Diseases; Urinary Bladder Diseases; Urinary Bladder Neoplasms
• Other Study ID Numbers: E7766-G000-102; 2019-000161-21 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Yes
• IPD Plan Description: Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No